AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Glimibose MV 1mg/500mg/0.2mg Tablet SR

Prescription Icon
Prescription Required

Marketer

B.J.Healthcare

Salt Composition

Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)

Overview Glimibose MV 1mg/500mg/0.2mg Tablet SR

This medication, a combined anti-diabetic agent known as Glimibose MV 1mg/500mg/0.2mg Tablet SR, is prescribed for adult patients with type 2 diabetes. Its purpose is to regulate blood glucose. Administer this extended-release tablet with food, consistently at the same time daily for optimal efficacy. Dosage is determined by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial; discontinuation without medical supervision can elevate blood sugar, potentially leading to kidney complications, vision loss, neuropathy, and limb damage. This drug complements a holistic diabetes management plan encompassing diet, exercise, and weight management as directed by your doctor. Lifestyle choices are integral to diabetes control. Hypoglycemia (low blood sugar) is a prevalent side effect. Learn to identify its symptoms (sweating, dizziness, headache, tremors) and implement appropriate countermeasures. Maintain regular meals and carry a readily available fast-acting glucose source (e.g., sugary snacks, fruit juice). Alcohol consumption should be limited due to its potential to exacerbate hypoglycemia. Additional possible side effects include altered taste, nausea, diarrhea, abdominal discomfort, headache, edema, visual disturbances, bone fractures, and upper respiratory infections. Weight gain may also occur. This medication is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or severe hepatic or renal impairment. Individuals with a history of heart disease should inform their physician before commencing treatment. Pregnant or lactating women require medical consultation prior to use. Regular blood glucose monitoring is essential, and your doctor may order blood tests to assess blood cell counts and liver function.

Uses of Glimibose MV 1mg/500mg/0.2mg Tablet SR

Managing type 2 diabetes

Major Benefits of Glimibose MV 1mg/500mg/0.2mg Tablet SR:

Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. The Glimibose MV 1mg/500mg/0.2mg Sustained-Release tablet should be taken on an empty stomach.

Common Side effects of Glimibose MV 1mg/500mg/0.2mg Tablet SR:

  • Nausea
  • Diarrhea
  • Abdominal pain
  • Hypoglycemia (low blood glucose level)
  • Loss of appetite

How to use Glimibose MV 1mg/500mg/0.2mg Tablet SR:

Administer this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the Glimibose MV 1mg/500mg/0.2mg Tablet SR whole; avoid chewing, crushing, or fracturing the tablet. Consume it on an empty stomach.

How Glimibose MV 1mg/500mg/0.2mg Tablet SR works:

A single tablet, Glimibose MV SR, combines 1mg, 500mg, and 0.2mg of three distinct antidiabetic agents.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Glimibose MV 1mg/500mg/0.2mg SR tablets with alcohol is inadvisable due to safety concerns.

PregnancyPregnancyCONSULT YOUR DOCTOR

The use of Glimibose MV 1mg/500mg/0.2mg SR tablets during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to the fetus. A physician will assess the potential advantages against any risks prior to prescribing this medication. Seek medical advice before taking this medicine.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Glimibose MV 1mg/500mg/0.2mg SR tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCAUTION

Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.

KidneyKidneyUNSAFE

The use of Glimibose MV 1mg/500mg/0.2mg SR tablets is likely unsafe for individuals with kidney impairment and should be omitted. Medical advice is recommended. Furthermore, this medication is not advised for patients experiencing severe kidney dysfunction.

LiverLiverCAUTION

Patients with liver disease should use Glimibose MV 1mg/500mg/0.2mg Tablet SR cautiously, potentially requiring dose modification. Consult a physician. Individuals with mild to moderate liver impairment should begin with a low dose of Glimibose MV 1mg/500mg/0.2mg Tablet SR; however, its use is contraindicated in those with severe liver disease.

What if you forget to take Glimibose MV 1mg/500mg/0.2mg Tablet SR :

Should you forget to take a Glimibose MV 1mg/500mg/0.2mg Tablet SR, administer it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Glimibose MV 1mg/500mg/0.2mg Tablet SR

LabelValue
Potential for Dependence None.
Medication Category Medication for diabetes

FAQs on Glimibose MV 1mg/500mg/0.2mg Tablet SR

Glimibose MV 1mg/500mg/0.2mg SR tablets contain glimepiride, metformin, and voglibose. This triple-drug formulation manages type 2 diabetes mellitus in adults. Effective blood sugar control requires concurrent adherence to a healthy diet and regular physical activity. Glimepiride stimulates insulin secretion from the pancreas, reducing blood glucose. Metformin decreases hepatic glucose production and enhances insulin sensitivity. Voglibose, an alpha-glucosidase inhibitor, reduces post-meal blood sugar spikes. This medication is unsuitable for treating type 1 diabetes.
Glimibose MV 1mg/500mg/0.2mg SR tablets may cause common adverse reactions including low blood glucose, nausea, diarrhea, taste disturbances, gas, abdominal discomfort, headache, skin eruptions, and upper respiratory infections.
Patients with hypersensitivity to any constituent or inactive ingredient in Glimibose MV 1mg/500mg/0.2mg Tablet SR should not take this medication. This medicine is contraindicated in individuals with moderate to severe renal impairment, and those suffering from inflammatory bowel disease, colonic ulcers, or underlying metabolic acidosis, such as diabetic ketoacidosis.
Combining Glimibose MV 1mg/500mg/0.2mg SR tablets with alcohol is unsafe. This combination can cause dangerously low blood sugar (hypoglycemia) and raise the risk of lactic acidosis.
Indeed, Glimibose MV 1mg/500mg/0.2mg SR tablets can lead to hypoglycemia. Low blood sugar may manifest as nausea, headache, irritability, hunger pangs, sweating, lightheadedness, tachycardia, and feelings of anxiety or tremor. The risk increases with skipped or delayed meals, alcohol consumption, excessive physical activity, or concomitant use of other antidiabetic medications. Therefore, consistent blood glucose monitoring is crucial. Carrying glucose tablets, honey, or fruit juice is recommended.
Retain this medication within its original, sealed packaging. Follow the storage directions provided on the package or label. Discard any leftover medication. Prevent access by children, pets, and others.
Glimibose MV 1mg/500mg/0....
74
MRP 90
17% off